Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Rheumatoid Arthritis Bone Quality (BAREBONE)
NCT03701789Phase 3Unknown
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Sep 2018
- Primary completion
- Oct 2021
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of baricitinib in rheumatoid arthritis (RA), sponsored by FAU Erlangen-Nürnberg Medical Faculty. Primary endpoint: Volumetric Bone Mineral Density at 52 weeks. Status: unknown.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03701789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03701789.